Swiss Traveler Returns Infected with Clade Ib Mpox

The Switzerland Federal Office of Public Health today reported its first case of Clade Ib mpox in an individual who had returned from Africa.

On April 8, 2025, the Swiss government stated that this person was in isolation and that there was no risk of infection to others.

The treatment of mpox consists primarily of treating its symptoms. In particularly severe cases, an antiviral therapy may also be conducted. The appropriate medicine is available in Switzerland in 2025.

Since September 2023, the World Health Organization has observed increased infections, especially of a new mpox variant designated Clade Ib, in Several African countries, including the Democratic Republic of the Congo.

The other well-known Clade II began infecting people worldwide in May 2022. 

A preventive vaccination (Jynneos®) is assumed to be effective against Clade I infection. The vaccine is safe and highly effective in preventing severe mpox infections.

Jynneos is also available in numerous countries, such as the United States.